Our Services
Medical Information
Helpful Resources
Published on: 3/12/2026
Auvelity, an FDA approved combination of dextromethorphan and bupropion, may deliver relief within about 1 week for some adults with major depressive disorder, especially when SSRIs or SNRIs have not helped, by targeting NMDA glutamate, dopamine, and norepinephrine rather than just serotonin. Trials show faster and greater symptom reduction versus placebo, though not everyone responds this quickly.
There are several factors to consider, including side effects like dizziness and insomnia, increased blood pressure, seizure risk, suicidality warnings, who should avoid it, drug interactions, cost, and the need for close monitoring. See below for the complete details, real world reviews, and the specific next steps to discuss with your clinician.
If you've tried one or more antidepressants and still feel stuck, you're not alone. Many people with major depressive disorder (MDD) do not get full relief from their first medication. That's why Auvelity reviews have been getting attention. This newer prescription medication works differently from traditional antidepressants—and for some people, it may start working faster.
But is it right for you? Let's break down what credible research shows, what real-world Auvelity reviews are saying, and what you should consider before making any changes.
Auvelity is an FDA-approved medication for major depressive disorder (MDD) in adults. It combines two medicines:
This combination works differently from common antidepressants like SSRIs (such as sertraline or fluoxetine), which mainly target serotonin.
Instead of focusing only on serotonin, Auvelity acts on:
This matters because depression is more complex than just "low serotonin." For some people, targeting multiple brain systems may lead to better results.
There are two main reasons:
In clinical trials, some patients reported improvement in depressive symptoms in as little as 1 week. That's significant because traditional antidepressants often take 4–6 weeks to show full effects.
In controlled studies:
That "1-week step" is one reason many Auvelity reviews describe it as a turning point after months or years of frustration.
However, not everyone responds in a week. Some people still require several weeks to feel meaningful change.
Up to 30–50% of people with depression do not respond fully to their first antidepressant. When SSRIs and SNRIs fail, doctors may try:
Auvelity offers another option because it works on glutamate pathways, similar in concept (but not identical) to ketamine-based treatments.
Some patients in published trials had previously used other antidepressants without full relief. In that group, Auvelity still showed measurable improvement.
That's why many online Auvelity reviews come from people who say things like:
Still, results vary. No antidepressant works for everyone.
According to FDA-reviewed clinical trial data:
Common side effects include:
Serious risks can include:
This is why medical screening is essential before starting.
Based on clinical guidance and emerging Auvelity reviews, it may be worth discussing with your doctor if:
It may not be appropriate if you:
A full medication review is critical.
While individual experiences vary, common themes include:
It's important to remember: online Auvelity reviews represent personal stories—not medical conclusions. Some people have dramatic improvements. Others notice only mild changes. A smaller group may discontinue due to side effects.
The idea of a 1-week shift is exciting. But here's the balanced truth:
Medication is one tool—not the entire solution.
If you're not sure whether what you're experiencing is actually depression or how severe your symptoms may be, Ubie's free AI-powered Depression Symptom Checker can help you assess your symptoms in just a few minutes and give you personalized insights before your next doctor's appointment.
Depression itself can be serious and, in some cases, life-threatening. If you experience:
You should seek immediate medical attention.
Antidepressants, including Auvelity, carry a boxed warning about increased suicidal thoughts in some younger patients, particularly early in treatment. Close monitoring during the first few weeks is essential.
Always speak to a doctor before:
Abrupt changes can be dangerous.
Not necessarily "better"—but different.
SSRIs:
Auvelity:
For some people, SSRIs work extremely well and are well tolerated. For others, they don't provide enough relief. That's where alternatives like Auvelity may fit in.
Treatment decisions should be individualized.
Because Auvelity is newer, insurance coverage varies. Some patients report higher out-of-pocket costs compared to generic antidepressants.
Before starting:
Financial stress can worsen depression, so planning ahead matters.
Auvelity reviews reflect real experiences—but they're not medical advice.
The credible clinical data shows:
If you feel like your current medication isn't working, that doesn't mean you're out of options. It means it's time for a new conversation.
Depression is treatable. But it often requires:
If your symptoms feel persistent, worsening, or overwhelming, speak to a doctor promptly. Depression is serious—but it is also highly treatable with the right support.
You don't have to figure this out alone.
(References)
* Auvelity (Dextromethorphan/Bupropion) for Major Depressive Disorder. Drugs. 2022 Sep;82(13):1413-1422. doi: 10.1007/s40265-022-01777-6. PMID: 36040713.
* The Efficacy and Safety of AXS-05 in Patients with Major Depressive Disorder: The GEMINI Randomized Clinical Trial. J Clin Psychiatry. 2021 Jul 27;82(4):20m13753. doi: 10.4088/JCP.20m13753. PMID: 34320078.
* Rapid Antidepressant Effects of AXS-05 (Dextromethorphan-Bupropion) in Patients with Major Depressive Disorder: The ASCEND Study. J Clin Psychiatry. 2020 Sep 22;81(5):20m13348. doi: 10.4088/JCP.20m13348. PMID: 32970732.
* Efficacy and safety of AXS-05 in patients with major depressive disorder and an inadequate response to prior antidepressant treatment: The STRIDE-1 study. J Affect Disord. 2023 Feb 1;322:201-209. doi: 10.1016/j.jad.2022.10.093. Epub 2022 Nov 2. PMID: 36328014.
* Dextromethorphan/Bupropion for Major Depressive Disorder: A Review of Efficacy and Safety. CNS Drugs. 2023 Feb;37(2):123-132. doi: 10.1007/s40263-022-00971-1. PMID: 36585642.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.